Select therapeutic use:
Indications for RYANODEX:
Treatment of malignant hyperthermia (MH) in conjunction with appropriate supportive measures. Prevention of malignant hyperthermia in high-risk patients.
Adults and Children:
Treatment: Give by IV push at a minimum of 1mg/kg; if psychologic and metabolic abnormalities continues or reappear, repeat dosing; max cumulative dose: 10mg/kg. Prevention: Start approx. 75 mins prior to surgery. 2.5mg/kg by IV over ≥1 min; may give additional doses if surgery prolonged.
Institute supportive measures (eg, discontinue MH-triggering agents, manage metabolic acidosis, cooling if necessary, diuretic administration). Monitor for skeletal muscle weakness, adequate ventilation, difficulty swallowing and choking. Avoid extravasation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid MH-triggering agents. Increased risk of somnolence or dizziness with concomitant sedative agents. Concomitant calcium channel blockers: not recommended. Concomitant other muscle relaxants may potentiate neuromuscular block. Increased CNS effects with concomitant antipsychotics, anxiolytics.
Muscle relaxant (skeletal).
Loss of grip strength, weakness in the legs, drowsiness, flushing, somnolence, dizziness, nausea, thrombophlebitis, tissue necrosis secondary to extravasation, urticaria, inj site reactions (eg, pain, erythema, swelling); dyspnea, dysphasia.
Single-use vial (20mL)—1 (w. diluent)